Published • loading... • Updated
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
- Ascletis Pharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC39, an oral treatment for obesity.
- Ascletis discovered ASC39 using its Artificial Intelligence-assisted Structure-Based Drug Discovery technology, which produced a unique chemical scaffold.
- The company reported that ASC39 was 40 times more selective for hAMY1R than hCTR, compared with 64 times for eloralintide.
- In a six-day rat study, daily oral ASC39 produced 6.6% placebo-adjusted weight loss, and Ascletis expects to begin a Phase I trial in late 2026.
Insights by Ground AI
40 Articles
40 Articles
Appalachian News-Express+39 Reposted by 39 other sources
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.
Coverage Details
Total News Sources40
Leaning Left4Leaning Right4Center27Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
12%
C 77%
11%
Factuality
To view factuality data please Upgrade to Premium
